clinical trial · NCT05986591
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
COPDTest Product - Tiotropium Bromide Inhalation Powder 18 mcgSpiriva Handihaler (Tiotropium Bromide) 18 mcgPlacebo
brief summary
Bioequivalence Study of Tiotropium Bromide Inhalation Powder 18 μg
started
Aug 17, 2022
primary completion
Aug 11, 2023
completion
Aug 14, 2023
last updated
Jan 31, 2024
detailed description
Pharmacodynamic bioequivalence study after a single dose of Tiotropium Bromide Inhalation Powder 18 μg vs Spiriva Handihaler (Tiotropium Bromide) 18 mcg
official title
A Multicenter, Randomized, Placebo-Controlled, Crossover, Single Dose Study To Demonstrate Clinical Pharmacodynamic Bioequivalence of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol